Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione maleic acid salt

Abstract

A hydrate of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt, characterised in that it: (i) comprises water in the range of from 0.2 to 1.1% w/w ; and (ii) provides an infra red spectrum containing peaks at 764 and 579 cm −1 ; and/or (iii) provides an X-ray powder diffraction (XRPD) pattern substantially as set out in Figure II; a process for the preparation of such a compound, a pharmaceutical composition containing such a compound and the use of such a compound or composition in medicine.

1 . A hydrate of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt, characterised in that it: 
 (i) comprises water in the range of from 0.2 to 1.1% w/w; and    (ii) provides an infra red spectrum containing peaks at 764 and 579 cm −1 ; and/or    (iii) provides an X-ray powder diffraction (XRPD) pattern substantially as set out in Figure II.    
   
   
       2 . A hydrate according to  claim 1 , wherein the water content is in the range of from 05 to 0.6% w/w.  
   
   
       3 . A hydrate according to  claim 1 , which provides an infra red spectrum substantially in accordance with Figure I.  
   
   
       4 . A hydrate according to  claim 1 , which provides an X-ray powder diffraction (XRPD) pattern substantially as set out in Figure II.  
   
   
       5 . A hydrate according to  claim 1 , in isolated form.  
   
   
       6 . A hydrate according to  claim 1 , in pure form.  
   
   
       7 . A hydrate according to  claim 1 , in crystalline form.  
   
   
       8 . A compound in the form of a rehydratable form of a hydrate according to  claim 1 .  
   
   
       9 . A process for preparing a hydrate according to  claim 1 , characterized in that 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt is crystallised from aqueous ethanol.  
   
   
       10 . A process according to  claim 11 , wherein the aqueous ethanol contains from 2% to 2.5% of water by volume.  
   
   
       11 . A pharmaceutical composition comprising an effective, non-toxic amount of a hydrate according to  claim 1  and a pharmaceutically acceptable carrier therefor.  
   
   
       12 . A hydrate according to  claim 1 , for use as an active therapeutic substance.  
   
   
       13 . A hydrate according to  claim 1 , for use in the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.  
   
   
       14 . A method for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, in a human or non-human mammal which comprises administering an effective, non-toxic, amount of Hydrate to a human or non-human mammal in need thereof.